Role of bacterial overgrowth in the stomach as an additional risk factor for gastritis

G Naylor, A Axon. Role of bacterial overgrowth in the stomach as an additional risk factor for gastritis. Can J Gastroenterol 2003;17(Suppl B):13B-17B.

Gastric bacteria can either be ingested or ascend from the distal bowel; however, their survival is usually limited by gastric acidity and motility. A decrease in gastric acid can result in bacterial overgrowth in the stomach and proximal small bowel, and the number of organisms rises as the intragastric pH rises.

The increased risk of non-cardia gastric cancer seen in patients with hypochlorhydria may be explained by an excess of nitrites and N-nitroso compounds (NOCs). These compounds are found in the diet of populations with a high gastric cancer risk, and can also be produced by the organisms that exist in the hypochlorhydria stomach. It has long been hypothesised that nitrites and NOCs act as one of the triggers in the atrophy-metaplasia-dysplasia-carcinoma path.

However, although indirect data have linked the premalignant changes of metaplasia and dysplasia to NOCs, direct measurement of gastric nitrites and NOCs has not confirmed such a link.

The role of Helicobacter pylori in bacterial overgrowth is mainly as a cause of hypochlorhydria resulting from atrophic gastritis, leading to a reduction in the parietal cell mass. Acid-suppressing drugs can result in bacterial overgrowth and increase nitrites and NOCs, although there is no current evidence for an increased risk of gastric cancer in patients taking them. One explanation is that the stomach appears to be colonized by different organisms than those in patients with hypochlorhydria for other reasons. There is some evidence that bacterial overgrowth per se can cause gastric inflammation in mice; however, although in humans the degree of gastric inflammation is greater when overgrowth is more prominent this may simply reflect the greater degree of hypochlorhydria in patients with a more severe H pylori-induced inflammation.

Key Words: Bacterial overgrowth; Gastritis; Hypochlorhydria; N-nitroso compounds.

Bacterial colonization of the upper gastrointestinal tract is usually prevented by a combination of acid secretion and intestinal motility. The upper gastrointestinal tract normally has less than $10^9$ colony-forming units (CFU)/mL and ‘bacterial overgrowth’ has been defined as counts of more than $10^5$ CFU/mL (1).

There are three possible sources of bacteria in the gastric lumen. They can be ingested with food, originate from the oropharyngeal cavity, or migrate from the small or large bowel lumen. They can be ingested with food, originate from the oropharyngeal cavity, or migrate from the small or large bowel lumen. They can be ingested with food, originate from the oropharyngeal cavity, or migrate from the small or large bowel lumen. They can be ingested with food, originate from the oropharyngeal cavity, or migrate from the small or large bowel lumen. They can be ingested with food, originate from the oropharyngeal cavity, or migrate from the small or large bowel lumen. They can be ingested with food, originate from the oropharyngeal cavity, or migrate from the small or large bowel lumen. They can be ingested with food, originate from the oropharyngeal cavity, or migrate from the small or large bowel lumen. They can be ingested with food, originate from the oropharyngeal cavity, or migrate from the small or large bowel lumen. They can be ingested with food, originate from the oropharyngeal cavity, or migrate from the small or large bowel lumen. They can be ingested with food, originate from the oropharyngeal cavity, or migrate from the small or large bowel lumen.

and enter the stomach by enterogastric reflux. There is a large variation in the ability of different organisms to survive in the acidic environment of the stomach (2). Most enteric pathogens have the ability to survive in an acidic environment to some extent. Helicobacter pylori (3) occupies a specific niche because it is able to colonize the stomach by using urease to produce an alkaline buffer zone of ammonia around itself. Yersinia enterocolitica also possesses a urease gene and can increase urease production as the pH decreases (4). Escherichia

This article was originally presented at a conference entitled “Helicobacter pylori: Basic Mechanisms to Clinical Cure 2002”, sponsored by Axcan Pharma, November 10-14, 2002, Maui, Hawaii

Centre for Digestive Diseases, Department of Gastroenterology, The General Infirmary at Leeds, Leeds, United Kingdom

Correspondence: Dr Anthony Axon, Centre for Digestive Diseases, Department of Gastroenterology, Room 190A, Clarendon Wing, The General Infirmary at Leeds, Great George Street, Leeds, LS1 3EX, United Kingdom. Telephone 44-113-392-2125, fax 44-113-392-6968, e-mail anthony.axon@leedsth.nhs.uk

©2003 Pulsus Group Inc. All rights reserved
Naylor and Axon

COPYRIGHT PULSUS GROUP INC. - DO NOT COPY

TABLE 1
Studies of bacterial overgrowth, nitrite increase and nitrosation following treatment with acid-inhibitory drugs

| Year (reference) | Number in study | Acid-inhibitory drug | Bacteria in gastric juice | Bacteriology test | Nitrite | Nitrosamine |
|-----------------|----------------|----------------------|--------------------------|------------------|--------|------------|
| 1980 (11)       | 31             | Cimetidine           | Increase                 | Culture          | NE     | NE         |
| 1981 (48)       | 407            | Cimetidine           | Increase                 | Culture          | Increase| Increase |
| 1982 (44)       | 23             | Cimetidine 1 g daily | Increase                 | Culture          | Increase| Increase |
| 1982 (50)       | 8              | Cimetidine           | Increase (resembling mouth flora) | Culture | NE     | NE         |
| 1984 (51)       | 30             | Cimetidine 400 mg BD | No evidence of bacterial overgrowth | H2 breath test | NE     | NE         |
| 1984 (52)       | 4              | Ranitidine           | Increase (not nitrate reducing) | Culture | No increase | No increase |
| 1984 (12)       | 10             | Omeprazole 30 mg daily | Increase                 | Culture          | Increase| Increase |
| 1994 (53)       | 14             | Omeprazole 20 mg daily | Increase                 | Culture          | Increase| Increase |
| 1996 (14)       | 47             | Cimetidine 800 mg or omeprazole 20 mg daily | Increase in bacteria in gastric juice in 53% omeprazole, 17% cimetidine | Culture | No increase | No increase |
| 1996 (54)       | 73             | Cimetidine           | Increase                 | Culture          | NE     | NE         |
| 2000 (55)       | 14             | Omeprazole 20 mg daily | Increase                 | Culture          | Increase| No increase |
| 2000 (31)       | 29             | Omeprazole           | Increase                 | Culture          | Increase| NE         |

BD Twice daily; NE Not examined

coli and Shigella flexneri can both survive exposure to a pH of 2.0 to 2.5. Salmonella typhimurium will not normally tolerate a pH of 3 but is able to mount an acid tolerance response that allows it to adapt and multiply at a lower pH (5). Differences in the ability to cope with an acidic environment may account for the infective dose of such enteric pathogens as S typhimurium being 10^3 organisms while S flexneri may only need 10 organisms to be ingested. As the pH rises, so does the number of organisms. Gastric colonization is proportional to both the pH and the time spent above a pH of 3.8 (6,7).

Bacterial overgrowth is associated with an increased risk of noncardia gastric cancer as seen in patients with hypochlorhydria due to pernicious anemia (8), atrophic gastritis (9) or partial gastrectomy (10). The principal hypothesis of carcinogenesis is based on evidence that bacterial overgrowth results in the production of nitrite from nitrate with subsequent production of carcinogenic N-nitroso compounds (NOCs). The purpose of the present review is to explore the relationship between bacterial overgrowth and gastric mucosal inflammation.

CAUSES OF BACTERIAL OVERGROWTH
Reduction in gastric acid from any cause may result in bacterial overgrowth in the stomach and the small intestine. Autoimmune gastritis resulting from the production of parietal cell antibodies in pernicious anemia is the classical natural cause. Distal gastrectomy (removing the gastrin-producing G cells of the antrum) can also result in bacterial overgrowth. The introduction of pharmacological acid suppression, initially with H2 receptor antagonists (11) and more recently with proton pump inhibitors (PPIs) (12), induces bacterial colonization of the stomach (Table 1). However, chronic infection with H pylori resulting in gastric atrophy and loss of parietal cell mass is the most common cause of hypochlorhydria and/or achlorhydria worldwide.

There appears to be a difference between the organisms found in the stomachs of patients with reduced acid due to autoimmune gastritis compared with those taking acid suppressing medication. In the former, coliforms predominate, while in the latter, Gram-positive organisms are found. The reasons for this are not clear but could relate to the shorter history of hypochlorhydria in acid suppression leading to colonization by organisms swallowed from the oropharynx (13,14).

H pylori status also appears to affect the degree of bacterial colonization (of non-Helicobacter species), especially in patients taking a PPI. H pylori-infected patients taking a PPI show a greater degree of colonization than do patients who are H pylori-negative. This is discussed in detail below.

CONSEQUENCES OF GASTRIC COLONIZATION
Enhanced nitrite production
Nitrites are required for the production of NOCs and can originate from three potential sources. They can be found in many foods such as cured meats, baked foods and cereals, while buccal and gastric bacteria can also convert dietary and/or salivary nitrate to nitrite. Twenty-five per cent of absorbed nitrate is secreted in the saliva and 40% of this is reduced to nitrite in the mouth. This appears to be due to reducing bacteria found in deep clefts at the back of the tongue. Swallowed nitrates can also be reduced to nitrites in the gastric lumen by colonizing bacteria. As the pH rises, the role of gastric bacteria as nitrite producers becomes more important, contributing 90% of nitrite load in a hypochlorhydria patient (15), and nitrite levels in gastric juice are also increased in these patients (16). Studies measuring gastric nitrite indirectly suggested a link between high concentrations of nitrite in gastric juice with an increased risk of gastric metaplasia, dysplasia and carcinoma, although this has not actually been confirmed by direct measurement (17). However, the persistence of nitrites in the stomach is dependent on the intragastric pH and the presence of ascorbic acid. At an acid pH and with ascorbic acid present, nitrites are rapidly reduced to nitric oxide, which can be detected in gas from the stomachs of individuals with normal acid secretion (18). Ascorbic acid is actively secreted by healthy gastric mucosa; however, its secretion is reduced in hypochlorhydric gastric juice. Hence, nitrites will persist because both of the factors needed for their conversion to nitric oxide (ascorbic acid and gastric acid) are decreased.

Production of NOCs
NOCs are composed of nitrosamides (R2NNOCOR2) and nitrosamines (R3NNOR3). They are recognized carcinogens in animals and can induce gastric cancer in rodents. They can be formed in the gastric lumen from the nitrosation of primary, secondary and tertiary amines, amino acids, peptides, amides, imides, bile acids, guanidines and urea.
Acetaldehyde production and bacterial overgrowth
Acetaldehyde (31) is a known carcinogen (32). Bacterial overgrowth in the hypochlorhydric stomach enhances the production of acetaldehyde from ethanol after ingestion. Acetaldehyde levels are also higher in alcohol dehydrogenase deficient individuals (common in the Far East). Alcohol does not necessarily need to be ingested because bacterial and yeast overgrowth can result in endogenous ethanol production.

Treatment with a PPI increases acetaldehyde production from ethanol in the gastric juice, probably as a result of bacterial overgrowth. Several organisms are associated with acetaldehyde production, including Neisseria, Stomatococcus and Streptococcus species. Therefore, acetaldehyde could be considered together with NOCs as potential gastric carcinogens.

Effects of bacterial overgrowth on the gastric mucosa
The reduction of nitrates to nitrites and the subsequent production of NOCs have been the principal focus of the effect of bacterial overgrowth in the stomach. Could bacterial overgrowth affect the gastric mucosa by any other mechanisms?

Bacterial overgrowth as a risk factor for gastritis
Zavros et al (33), using a mouse model, studied wild type (gastrin secreting [G+]I) and genetically achlorhydric (nongastrin secreting [G–]) mice. Initial assessment of gastric pathology in both groups revealed greater inflammation in the G– mice. There were also higher bacterial counts in the antrum of G– mice than in G+ mice. Groups of both genotypes were then treated with antibiotics until the feces showed no bacterial growth. The gastritis was then reassessed and found to have resolved in the G– mice. Treatment of the G+ mice with omeprazole led to an increase in bacterial count and an increase in gastritis that was reduced by subsequent antibiotic treatment (33). The bacterial species were typed and found to be similar in both genotypes. No H pylori or other urea-producing Helicobacter species were present and, hence, could not be a cause of the inflammation.

The authors concluded that bacterial overgrowth contributed to the inflammatory response in the stomach. It was noted that in both genetically and pharmacologically induced hypochlorhydria gastritis increased as bacterial overgrowth increased. However, there was a discrepancy in the magnitude of change of inflammation compared with the magnitude of change of bacterial numbers. This suggested that other factors, perhaps those related to bacterial metabolism, contributed to the degree of inflammation. Because NOCs were not measured, it is difficult to assess their role in this scenario, although there is no other evidence that they are pro-inflammatory.

If bacterial overgrowth contributes to inflammation in humans, we would expect to see evidence of it in patients receiving PPI treatment. Kuipers et al (34) studied the incidence of atrophic gastritis in H pylori-positive and negative gastroesophageal reflux patients treated with PPI or antireflux surgery. H pylori-negative patients were found to have a mild gastritis in seven of 46 patients before PPI treatment. After a mean follow-up of five years, moderate to severe corpus gastritis had developed in only two patients (4%). This was associated with atrophy and corresponded to an annual increase of 0.8%. There was no evidence of intestinal metaplasia. In comparison, the incidence of gastritis in the PPI-treated H pylori-infected group increased from 59% to 81% and atrophy from 0% to 31%. In the H pylori-negative surgical group, there was no evidence of inflammation or atrophy before treatment or after a mean follow-up of five years. The H pylori-positive surgical cohort showed no change in prevalence or severity of gastritis, and none of the patients developed atrophy. Is the 4% incidence of gastritis in the H pylori-negative PPI cohort evidence that bacterial overgrowth induces gastritis?

A study by Lundell et al (35) did not find any association between H pylori infection, PPI treatment and the development of gastric atrophy. There was no evidence of gastric inflammation in the H pylori-negative group either before or after treatment. There was a trend to atrophy in the H pylori-positive group that did not reach statistical significance, but other studies support Kuipers’ results, suggesting an annual incidence of atrophy of 3.8% to 8.7% (35-40). Klinkenberg-Knol et al (36, 37) found an annual incidence of atrophy of 0.7% in H pylori-negative subjects on PPI treatment (4.7% in H pylori-positive subjects). There was also an increase in the severity of gastritis in this cohort but the exact numbers are not given in the published results. These data suggest that severe gastric inflammation associated with atrophy occurs in less than 1% per year in H pylori-negative patients treated with a PPI. This does not support the hypothesis proposed by the Zavros et al (33) study.
which showed, in mice, that bacterial overgrowth alone can result in gastric inflammation.

Sanduleanu and colleagues (41,42) have addressed this issue in two papers. They have shown that non-H\textit{ pylori} flora (both luminal and mucosally associated) was significantly increased in those patients on acid suppression therapy who were infected with \textit{Helicobacter} species than those who were not. In their second paper, they showed that the simultaneous presence of \textit{H pylori} and non-\textit{H pylori} bacteria was associated with a 20-fold increased risk of developing atrophic gastritis, suggesting a synergistic effect between the two infections. The weakness of their hypothesis, however, is that the greater the atrophy, the lower will be the acid secretion and, consequently, the greater the bacterial overgrowth. In other words, the increased bacterial overgrowth may reflect the higher degree of atrophy rather than vice versa. Nevertheless, the hypothesis is interesting and more research is needed in this area.

**Bacterial overgrowth and bile acid metabolism**

Bile reflux into the stomach is associated with an increased incidence of intestinal metaplasia (43). Some species of bacteria colonizing the stomach and small intestine during bacterial overgrowth are capable of deconjugating bile acids. Much of the attention has been focused on the role that bile plays in gastroesophageal reflux disease. The concentration of bile acids reaching the esophagus and their toxic effects are known to vary with pH depending on the degree of ionization (44). Unconjugated bile acids tend to precipitate in solutions with a pH lower than 4. Esophageal perfusion studies in animal models have shown that unconjugated bile acids can cause mucosal damage in alkaline solutions (45,46); however, no equivalent data exist for the effect of unconjugated bile acids on the gastric mucosa. Bile acids can also act as a substrate for nitrosation to produce NOCs and there is evidence of genotoxicity from these products (47).

**CONCLUSION**

\textit{Non-H pylori} bacterial colonization of the stomach occurs when the pH of the gastric juice rises. The number of bacteria present increases as the pH increases, and the resulting organisms can be of oropharyngeal or fecal origin. Decreased gastric acid secretion for any reason can lead to bacterial overgrowth; both \textit{H2} receptor antagonists and PPIs are known to cause it. Many organisms metabolize nitrate to nitrite and others are capable of inducing nitrosation to NOCs. They may also increase acetaldehyde production and deconjugate bile salts. It is unclear whether these metabolic activities or others as yet undefined may increase the gastric inflammatory response in the human hypochlorhydric stomach. There is good evidence that gastric bacterial overgrowth per se causes inflammation in the stomachs of mice, and some data in humans show that the inflammatory response is greater when overgrowth is prominent, but this finding may merely reflect the greater degree of hypochlorhydria in those patients with a more severe \textit{H pylori}-induced inflammation.

**REFERENCES**

1. Evenepoel P. Alteration in digestion and absorption of nutrients during profound acid suppression. Best Pract Res Clin Gastroenterol 2001;15:533-9.

2. Howden CW, Hunt RH. Relationship between gastric secretion and gastric bacterial overgrowth. J Clin Gastroenterol 1995;20:132-40.

3. Marshall BJ, Barrett LJ, Prakash C, McCallum RW, Guerrant RL. Ulcers in patients with gastroesophageal reflux disease. The concentration of bile acids reaching the esophagus and their toxic effects are known to vary with pH depending on the degree of ionization (44).

4. Lin J, Lee IS, Frey J, Slonczewski JL, Foster JW. Comparative analysis of urease activity and nitrosation before, during, and after treatment with omeprazole. Best Pract Res Clin Gastroenterol 1995;15:539-51.

5. Naylor and Axon. \textit{Am J Clin Nutr} 1991;53(Suppl 1):270S-82S.

6. Sanduleanu and colleagues (41,42) have addressed this issue in two papers. They have shown that non-\textit{H pylori} flora (both luminal and mucosally associated) was significantly increased in those patients on acid suppression therapy who were infected with \textit{Helicobacter} species than those who were not. In their second paper, they showed that the simultaneous presence of \textit{H pylori} and non-\textit{H pylori} bacteria was associated with a 20-fold increased risk of developing atrophic gastritis, suggesting a synergistic effect between the two infections. The weakness of their hypothesis, however, is that the greater the atrophy, the lower will be the acid secretion and, consequently, the greater the bacterial overgrowth. In other words, the increased bacterial overgrowth may reflect the higher degree of atrophy rather than vice versa. Nevertheless, the hypothesis is interesting and more research is needed in this area.

7. Theisen J, Nehra D, Citron D, et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg 2002;7:40-9.

8. Young GM, Amid D, Miller VL. A bifunctional urease enhances the bactericidal effect of acid. Gastroenterology 1990;99:697-702.

9. Young GM, Amid D, Miller VL. A bifunctional urease enhances survival of pathogenic \textit{Versinia enterococida} and \textit{Morganella morganii} at low pH. J Bacteriol 1995;178:6487-95.

10. Lin J, Lee IS, Frey J, Slonczewski JL, Foster JW. Comparative analysis of urease activity and nitrosation before, during, and after treatment with omeprazole. Best Pract Res Clin Gastroenterol 1995;15:539-51.

11. Ruddell WSJ, Bone ES, Hill MJ, Blends LM, Walters CL. Gastric juice nitrite: a risk factor for cancer in the hypochlorhydric stomach. Lancet 1976;2:1037-9.

12. Sobala GM, Fignatelli B, Schorah CJ, et al. Levels of nitrite, nitrate, N-nitroso compounds, ascorbic acid and total bile acids in gastric juice of patients with and without precancerous conditions of the stomach. Carcinogenesis 1991;12:193-8.

13. Smulian T, Miki K, Kimmey M, et al. Chronic atrophic gastritis and \textit{Helicobacter pylori} infection among Japanese Americans in Seattle. Am J Epidemiol 2000;151:820-30.

14. Smulian T, Miki K, Kimmey M, et al. Chronic atrophic gastritis and \textit{Helicobacter pylori} infection among Japanese Americans in Seattle. Am J Epidemiol 2000;151:820-30.

15. Eisenbrand G, Adam B, Peter M, Malferttheiner P, Schlag P. Formation of nitrite in gastric juice of patients with various gastric disorders after ingestion of a standard dose of nitrate – a possible risk factor in gastric carcinogenesis. IARC Sci Publ 1984;57:963-8.

16. Kobayashi Y, Ishida Y, Yamasaki M, et al. Influence of gastric pH on gastric and jejunal flora. Gut 1968;7:74-81.

17. Theisen J, Nehra D, Citron D, et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg 2002;7:40-9.

18. Hsing AW, Hanson LE, McLaughlin JK, et al. Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer 1999;7:745-50.

19. Yamasaki M, Ishida Y, Kobayashi Y, et al. Influence of gastric pH on gastric and jejunal flora. Gut 1968;7:74-81.

20. Smulian T, Miki K, Kimmey M, et al. Chronic atrophic gastritis and \textit{Helicobacter pylori} infection among Japanese Americans in Seattle. Am J Epidemiol 2000;151:820-30.

21. Smulian T, Miki K, Kimmey M, et al. Chronic atrophic gastritis and \textit{Helicobacter pylori} infection among Japanese Americans in Seattle. Am J Epidemiol 2000;151:820-30.
Bacterial overgrowth as a risk factor for gastritis

40. Kuipers EJ, Jonkers D, De Bruine A, Hameeteman W, Stockbrugger RW. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther 2001;15:379-88.

41. Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrugger RW. Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis. Aliment Pharmacol Ther 2001;15:1163-73.

42. Solbas OM, O’Connor HJ, Dewar EP, King RA, Axon ATR, Dixon ME. Bile reflux and intestinal metaplasia in gastric mucosa. J Clin Pathol 1993;46:235-40.

43. Nehra D, Howell P, Williams CP, Pye JK, Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 1999;44:598-602.

44. Niraula S, Fromm D, Silen W. Effect of bile salts and related compounds on isolated esophageal mucosa. Surgery 1980;88:280-5.

45. Lildlme KD, Johnson LE, Harmon JW. Role of the components of the gastroduodenal contents in experimental acid esophagitis. Surgery 1982;92:276-84.

46. Pujol P, Smith PL, Haines K, House FR, Walters CL. Effect of cimetidine on gastric juice N-nitrosamine concentration. Lancet 1981;2:553-56.

47. Stockbrugger RW, Cotton PB, Eugenides N, Bartholomew BA, Hill MJ, Walters CL. Intragastric nitrates, nitrosamines and bacterial overgrowth during cimetidine treatment. Gut 1982;23:1048-54.

48. Snear P, Poporan GA, Romano JM, Kobasa WD, Kaye D. Effect of cimetidine and antacid on gastric microbial flora. Infect Immun 1982;36:518-24.

49. Mowat C, Williams C, Gillen D, et al. Omeprazole, ranitidine during a 24-hour period on the level of nitrates, nitrates, nitrosamines and bacterial flora in the gastric juice of healthy subjects. Gastroenterol Clin Biol 1984;8:749-53.

50. Verdue E, Viani F, Armstrong D, et al. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites and N-nitroso compounds. Gut 1994;35:455-60.

51. Stockbrugger RW. Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis. Aliment Pharmacol Ther 2001;15:1163-73.

52. Garcia del Risco F, Rolin O, Farinotti R, et al. Influence of bile salts and related compounds. Gut 1996;44:462-9.

53. Molitoris B, Stockbrugger RW. Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis. Aliment Pharmacol Ther 2001;15:1163-73.

54. Briner P, Smith PL, Haines K, House FR, Walters CL. Effect of cimetidine on gastric juice N-nitrosamine concentration. Lancet 1982;2:553-56.
